

NOVO NORDISK A S  
Form 6-K  
February 02, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

February 1, 2017

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F       Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_

#### **Novo Nordisk A/S - Share repurchase programme**

**Bagsværd, Denmark, 1 February 2017** – On 28 October 2016, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 3 February 2016.

Under the programme initiated 28 October 2016, Novo Nordisk will repurchase B shares for an amount up to DKK 4.5 billion in the period from 28 October 2016 to 31 January 2017. The programme is now concluded.

Since the announcement as of 23 January 2017, the following transactions have been made under the programme:

|  | <b>Number of<br/>B shares</b> | <b>Average<br/>purchase price</b> | <b>Transaction<br/>value, DKK</b> |
|--|-------------------------------|-----------------------------------|-----------------------------------|
| <b>Accumulated, last announcement</b>  | <b>16,740,210</b>             |                                   | <b>4,045,049,995</b>              |
| 23 January 2017                        | 305,000                       | 246.10                            | 75,060,654                        |
| 24 January 2017                        | 290,000                       | 242.66                            | 70,372,550                        |
| 25 January 2017                        | 250,000                       | 241.07                            | 60,267,279                        |
| 26 January 2017                        | 240,000                       | 245.06                            | 58,815,596                        |
| 27 January 2017                        | 250,000                       | 245.97                            | 61,492,081                        |
| 30 January 2017                        | 260,000                       | 247.72                            | 64,408,372                        |
| 31 January 2017                        | 260,484                       | 248.67                            | 64,774,912                        |
| <b>Accumulated under the programme</b> | <b>18,595,694</b>             |                                   | <b>4,500,241,439</b>              |

The details for each transaction made under the share repurchase programme are published on [novonordisk.com](http://novonordisk.com).

With the transactions stated above, Novo Nordisk owns a total of 51,694,676 B shares of DKK 0.20, corresponding to 2.0% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,550,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 3 February 2016. As of 31 January 2017, Novo Nordisk has repurchased a total of 49,771,031 B shares equal to a transaction value of DKK 14,999,999,885.

*Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com), Facebook, Twitter, LinkedIn, YouTube*

## Further information

### Media:

|                      |                 |  |
|----------------------|-----------------|--|
| Anne Margrethe Hauge | +45 4442 3450   | <a href="mailto:amhg@novonordisk.com">amhg@novonordisk.com</a> |
| Ken Inchausti (US)   | +1 609 786 8316 | <a href="mailto:kiau@novonordisk.com">kiau@novonordisk.com</a> |

### Investors:

|                         |                 |  |
|-------------------------|-----------------|--|
| Peter Hugrefte Ankersen | +45 3075 9085   | <a href="mailto:phak@novonordisk.com">phak@novonordisk.com</a> |
| Melanie Raouzeos        | +45 3075 3479   | <a href="mailto:mrz@novonordisk.com">mrz@novonordisk.com</a>   |
| Hanna Ögren             | +45 3079 8519   | <a href="mailto:haoe@novonordisk.com">haoe@novonordisk.com</a> |
| Anders Mikkelsen        | +45 3079 4461   | <a href="mailto:armk@novonordisk.com">armk@novonordisk.com</a> |
| Kasper Veje (US)        | +1 609 235 8567 | <a href="mailto:kpvj@novonordisk.com">kpvj@novonordisk.com</a> |

|                         |               |               |  |
|-------------------------|---------------|---------------|--|
| <b>Novo Nordisk A/S</b> | Novo Allé     | Telephone:    | Internet:  |
| Investor Relations      | 2880 Bagsværd | +45 4444 8888 | <a href="http://www.novonordisk.com">www.novonordisk.com</a> |
|                         | Denmark       |               | CVR no:  |
|                         |               |               | 24 25 67 90  |

Company announcement No 6 / 2017

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: February 1, 2017

Lars Rebien Sørensen,

Chief Executive Officer